10-K: Liquidia Corporation Outlines Financials, Pipeline and Legal Matters in 10-K Filing

Sentiment:

Annual Results 13 March 2024 7:30 AM

Liquidia Corporation's 10-K filing details its financial status, product pipeline, ongoing litigation, and strategic agreements.

Delay expectedFinal FDA approval and launch of YUTREPIA are directly impacted by the Hatch-Waxman litigation commenced by United Therapeutics and the regulatory exclusivity that was granted to United Therapeutics with respect to PH-ILD, which expires on March 31, 2024.The FDA cannot issue a final approval for the YUTREPIA NDA until the resolution of the outstanding litigation and until expiration of United Therapeutics regulatory exclusivity.Final FDA approval and launch may also be impacted by other litigation commenced by United Therapeutics in which it is seeking to enjoin approval and launch of YUTREPIA.

Capital raiseThe company may need to raise additional funds to meet its future funding requirements for the continued research, development and commercialization of its product candidates and technology.The company may raise additional funds through the issuance of equity or debt securities or by borrowing from banks or other financial institutions.In January 2024, the company entered into a common stock purchase agreement with Legend Aggregator, LP for the sale of 7,182,532 shares of common stock at a purchase price of $10.442 per share for gross proceeds of approximately $75.0 million.

Worse than expectedThe company reported a net loss of $78.5 million for 2023, which is significantly worse than the $41.0 million net loss reported for 2022.

Summary

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing treatments for rare cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The company generates revenue through a promotion agreement with Sandoz for the sale of generic treprostinil injection, and is also developing its own product candidates, YUTREPIA and L606.
YUTREPIA, an inhaled dry powder formulation of treprostinil, received tentative FDA approval for PAH in November 2021, and an amendment to add PH-ILD was filed in July 2023.
Final FDA approval for YUTREPIA is pending resolution of ongoing litigation and the expiration of a competitor's exclusivity period on March 31, 2024.
L606, a liposomal formulation of treprostinil, is being evaluated in an open-label study for PAH and PH-ILD, with a planned pivotal study for PH-ILD.
The company reported a net loss of $78.5 million for the year ended December 31, 2023, and has an accumulated deficit of $429.1 million.
Liquidia has a financing facility with HCR, which requires mutual agreement for drawdowns and contains operating and financial covenants.
The company is involved in ongoing patent litigation with United Therapeutics, which could impact the approval and commercialization of YUTREPIA.
As of March 1, 2024, Liquidia employed 136 salaried and nine hourly employees.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the product pipeline and strategic agreements, the significant financial losses, ongoing litigation, and dependence on third parties create substantial risks and uncertainties. The sentiment is cautiously optimistic but with significant concerns.

Positives

YUTREPIA has shown to be safe, well-tolerated and effective in clinical studies, regardless of a patients previous exposure to treprostinil.
The company has a commercial presence in the field to support Treprostinil Injection, which can be leveraged for the potential launch of YUTREPIA.
Liquidia has a proprietary PRINT technology that allows for precise engineering of drug particles.
The company has a collaboration with Sandoz and Mainbridge to develop a new subcutaneous pump for infusion of Treprostinil Injection.
Liquidia has an exclusive license in North America to develop and commercialize L606, an inhaled, sustained-release formulation of treprostinil.

Negatives

Liquidia has incurred significant operating losses and has an accumulated deficit of $429.1 million.
The company is dependent on third parties for clinical and commercial supplies, including single suppliers for key components of YUTREPIA and L606.
Smiths Medical will discontinue support of the CADD-MS 3 infusion pumps on January 1, 2025, which is used to administer Treprostinil Injection subcutaneously.
The company is involved in ongoing patent litigation with United Therapeutics, which could impact the approval and commercialization of YUTREPIA.
The company may need further financing for its existing business and future growth, which may not be available on acceptable terms, if at all.

Risks

The company's future viability depends on its ability to raise additional capital.
The company is primarily dependent on the success of YUTREPIA and L606, which may fail to receive final marketing approval or may not be commercialized successfully.
Ongoing litigation with United Therapeutics could delay the commercialization of YUTREPIA or result in substantial damage claims.
The company is dependent on Sandoz, Chengdu, and pump manufacturers for the supply of Treprostinil Injection, the RG Cartridge, and pumps.
The company faces significant competition from large pharmaceutical companies in developing its products.
The company's financing facility with HCR contains operating and financial covenants that restrict its business and financing activities.
The company's products may not achieve market acceptance.
The company depends on third parties for clinical and commercial supplies, including single suppliers for key components of YUTREPIA and L606.
The company may become involved in litigation to protect its intellectual property, which could be expensive and time-consuming.
The company's business and operations may be adversely affected by health epidemics, including the COVID-19 pandemic.

Future Outlook

The company expects to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through clinical trials, seeks regulatory approval, and pursues commercialization. The company may need to raise additional funds to meet its future funding requirements.

Management Comments

Roger Jeffs, Chief Executive Officer of Liquidia, stated: L606 is the perfect life-cycle complement to our pipeline and furthers our mission to provide innovative treatment options that improve the lives of patients suffering from PAH or PH-ILD.
Pei Kan, Ph.D., President of Pharmosa, added: Liquidia is the ideal partner to bring L606 to the North American market.

Industry Context

The document highlights the competitive landscape in the pharmaceutical industry, particularly in the PAH and PH-ILD treatment areas, with several companies developing competing products and therapies. The document also notes the increasing emphasis on cost containment measures in the healthcare industry, which could impact the pricing and reimbursement of the company's products.

Comparison to Industry Standards

The document mentions that in 2023, the total reported net revenue of branded therapies approved to treat PAH and PH-ILD in the United States exceeded $5.5 billion, of which $3.4 billion targeted the prostacyclin pathway.
United Therapeutics reported that its class of branded treprostinil-based products generated U.S. net revenue of $1.98 billion in 2023, of which the Tyvaso franchise contributed $1.2 billion, Orenitram contributed $359 million and Remodulin contributed $415 million.
Since 2019, reported annual sales of products in the Tyvaso franchise have increased from $400 million to $1.2 billion, correlating with the expansion into the PH-ILD indication in 2021 and addition of Tyvaso DPI in 2022.
The document notes that generic drug prices may decline dramatically as competitors seek to secure preferential utilization though the specialty pharmacy and hospital distribution channels in which parenteral prostacyclin products are sold.
The document also mentions that in February 2021, United Therapeutics announced the commercial launch of the Remunity pump for Remodulin, which uses a small subcutaneous pump for patients starting or on a stable dose of Remodulin and can use prefilled Remodulin cassettes.

Legal Proceedings

United Therapeutics has initiated multiple lawsuits against the company in which it has claimed that YUTREPIA is infringing its patents.
United Therapeutics has initiated a separate lawsuit against the company that it and a former United Therapeutics employee, who later joined the company as an employee, conspired to misappropriate certain trade secrets of United Therapeutics and engaged in unfair or deceptive trade practices.
United Therapeutics has initiated a separate lawsuit against the FDA seeking to challenge the FDAs acceptance of the company's amended NDA for YUTREPIA.

Related Party Transactions

In December 2023, the company entered into a common stock purchase agreement with Roger Jeffs, the Chief Executive Officer of the Company, for the sale of 139,665 shares of common stock at a purchase price of $7.16 per share for gross proceeds of approximately $1.0 million.

Stakeholder Impact

Shareholders face the risk of potential losses due to the company's financial situation and ongoing litigation.
Employees may be affected by potential changes in the company's operations and financial stability.
Customers and patients may benefit from the development of new treatments for PAH and PH-ILD, but the availability of these treatments is subject to regulatory approval and commercialization challenges.
Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

The company is preparing to initiate a global placebo-controlled efficacy study in PH-ILD in late 2024.
The company anticipates that Mainbridge will submit a 510(k) in the first half of 2024 for FDA clearance of a new subcutaneous pump for infusion of Treprostinil Injection.
The company is actively conducting and considering other clinical trials to generate additional data to support the use of YUTREPIA.

Key Dates

Date	Description
December 23, 2019	Liquidia Technologies entered into a common stock purchase agreement for a private placement.
December 27, 2019	Liquidia Technologies issued and sold 7,164,534 shares of its common stock at a price of $3.13 per share.
February 3, 2020	Liquidia Technologies filed a registration statement with the SEC.
February 13, 2020	Liquidia Technologies registration statement was declared effective by the SEC.
June 29, 2020	Agreement and Plan of Merger by and among the Company, Liquidia Technologies and RareGen, LLC.
August 3, 2020	Limited Waiver and Modification to Agreement and Plan of Merger.
June 4, 2020	United Therapeutics commenced Hatch-Waxman litigation against Liquidia.
December 16, 2020	Liquidia filed a resale registration statement with the SEC.
December 23, 2020	Liquidia's resale registration statement was declared effective by the SEC.
November 2021	YUTREPIA received tentative FDA approval for PAH.
May 21, 2021	Chengdu Shifeng Medical Technologies LTD began selling the RG 3ml Medication Cartridge.
January 1, 2025	Smiths Medical will discontinue service and maintenance of CADD-MS 3 infusion pumps.
July 2023	Liquidia filed an amendment to its NDA to add PH-ILD to the label for YUTREPIA.
December 12, 2023	Liquidia entered into a common stock purchase agreement with Roger Jeffs.
January 4, 2024	Liquidia entered into a common stock purchase agreement with Legend Aggregator, LP.
March 31, 2024	The new clinical investigation exclusivity granted to Tyvaso in PH-ILD expires.

Keywords

Liquidia, YUTREPIA, Treprostinil, L606, PAH, PH-ILD, PRINT technology, Sandoz, Pharmosa, clinical trials, FDA approval, patent litigation, commercialization, biopharmaceutical

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.